Business, energy, technology, markets and global industry news from Business News Today

neuropathic pain

PharmaDeviceNews neuropathic pain
Researchers examine blood-based RNA biomarkers that could eventually support more objective assessment and treatment monitoring for neuropathic pain, as Lilac Biosciences and Soin Neuroscience outline a translational testing roadmap. Representative image.
Pharma & Biotech

Lilac Biosciences and Soin Neuroscience publish RNA biomarker review for neuropathic pain

Lilac Biosciences and Soin Neuroscience map an RNA biomarker path for neuropathic pain, but clinical validation remains the decisive test.

Read More
Pharma & Biotech

Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition

Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.

Read More
Representative image: A clinician discusses nerve pain research and treatment data with a patient, reflecting Lateral Pharma’s LanCL1 discovery and the search for new neuropathic pain drug targets.
Pharma & Biotech

Is Lateral Pharma’s pain platform quietly opening a new biotech battleground?

Find out how Lateral Pharma’s LanCL1 discovery could reshape neuropathic pain drug research and open a new biotech opportunity.

Read More